Qore Biotechnologies
Revolutionising
Cardiovascular Translational Research using Living Myocardial Slices
Novel organotypic in-vitro platform to investigate human cardiac function
ABOUT QORE
Redefining Pre-clinical Research with Human Heart Tissue
Qore Biotechnologies is a research team from Imperial College London and the University of Cambridge, participating in the BBSRC ICURe Explore programme to assess the market need for human-relevant preclinical models. Our living myocardial slices improve drug testing, toxicity screening, and disease modelling, offering a more accurate, cost-effective, and ethical alternative to traditional methods.
THE PROBLEM
Inefficient and Costly Preclinical Models
Current preclinical models for cardiovascular drug development, such as stem cell-derived cardiomyocytes and animal models, often lack the physiological complexity, cellular maturity, and relevance of the adult human myocardium. As a result, clinical trial success rates remain as low as 6%, despite over $700 million being spent on preclinical cardiovascular research per single drug.
We believe that integrating living myocardial slices into the preclinical research pipeline can significantly reduce costs and improve predictability by utilising adult human heart tissue for highly translatable drug screening, toxicology testing, and validation. This approach not only minimises costs associated with stem cell and animal studies but also streamlines drug development by allowing researchers to focus resources on the most promising therapeutic candidates, reducing time wasted on non-relevant models and enhancing overall efficiency.
OUR SOLUTION
Living Myocardial Slices
Living myocardial slices provide a highly predictive, efficient, and cost-effective solution for cardiovascular drug development by using adult human heart tissue. Unlike traditional preclinical models, our platform can obtain human-relevant data which could potentially reduce the risk of clinical trial failures and lower the costs associated with stem cells and animal research. By offering a service providing drug screening, toxicology testing, and functional assessments, we eliminate the need for customers to establish in-house platforms. Additionally, our adaptable system allows long-term culture of human tissue to mimic chronic cardiac diseases, the possibility to recreate disease models in vitro, providing a versatile and high-impact solution for accelerating cardiovascular drug discovery.
INDUSTRIES
Who We Serve
Pharmaceutical Companies
Improving drug efficacy testing and reducing failure rates.
Contract Research Organisations (CROs)
Enhancing preclinical drug validation with human-relevant models.
Academic Research Institutions
Supporting high-impact cardiovascular research and disease modelling.
Chemical & Environmental Industries
Enabling safer toxicity and cardiotoxicity screening.
Food & Nutraceutical Companies
Testing the effects of functional ingredients on heart health.
Fitness & Sports Science
Evaluating supplements and interventions for cardiovascular performance.
TAKE OUR SURVEY
Share Your Insights
We are conducting market research to understand the challenges faced in cardiovascular drug development, toxicity testing, and disease modelling. Your insights will help us assess the demand for human-relevant preclinical models and refine our technology to meet industry needs.
Who Should Participate?
Pharmaceutical & Biotech Companies
Contract Research Organisations (CROs)
Academic Researchers
Chemical & Environmental Industries
Nutraceutical & Sports Science Sectors
EXPERT TEAM
Meet our team
Our multidisciplinary team combines expertise in cardiovascular science, biotechnology, and commercialisation to bring cutting-edge research into real-world applications.
CEO
Laura Nicastro
CSO
Barrett Downing
COO
Franklin Lo
SCIENTIFIC ADVISOR
Professor Cesare Terracciano
Reach Us
Have questions or want to learn more about our work at Qore Biotechnologies? Fill out the form below, and our team will get back to you as soon as possible.